James Tobin Net Worth

The estimated Net Worth of James R Tobin is at least $26.7 millió dollars as of 8 August 2024. Mr. Tobin owns over 20,000 units of Globus Medical Inc stock worth over $11,993,823 and over the last 22 years he sold GMED stock worth over $14,286,742. In addition, he makes $406,959 as Independent Director at Globus Medical Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Tobin GMED stock SEC Form 4 insiders trading

James has made over 21 trades of the Globus Medical Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of GMED stock worth $3,186,600 on 8 August 2024.

The largest trade he's ever made was exercising 350,000 units of Globus Medical Inc stock on 9 October 2008 worth over $2,145,500. On average, James trades about 11,987 units every 76 days since 2003. As of 8 August 2024 he still owns at least 173,146 units of Globus Medical Inc stock.

You can see the complete history of Mr. Tobin stock trades at the bottom of the page.

James Tobin biography

James R. Tobin serves as Independent Director of the Company. Mr. Tobin served as President and Chief Executive Officer of Boston Scientific from March 1999 to July 2009. Before joining Boston Scientific, Mr. Tobin served Biogen, Inc. as its President and CEO from 1997 to 1998 and as its Chief Operating Officer from 1994 to 1997. Mr. Tobin served Baxter International in various capacities from 1972 to 1994, including as its President and Chief Operating Officer from 1992 to 1994. Mr. Tobin also currently serves on the board of directors of Oxford Immunotec Global PLC (NYSE: OXFD), a global diagnostics company, Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, and two private companies, TransMedics, Inc. and Resolys Bio, Inc. He served as Lieutenant in the U.S. Navy from 1968 to 1972. Mr. Tobin holds an M.B.A. from Harvard Business School and an A.B. from Harvard College.

What is the salary of James Tobin?

As the Independent Director of Globus Medical Inc, the total compensation of James Tobin at Globus Medical Inc is $406,959. There are 12 executives at Globus Medical Inc getting paid more, with David Demski having the highest compensation of $3,449,790.

How old is James Tobin?

James Tobin is 75, he's been the Independent Director of Globus Medical Inc since 2015. There are no older and 18 younger executives at Globus Medical Inc.

What's James Tobin's mailing address?

James's mailing address filed with the SEC is C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, ANDOVER, MA, 01810.

Insiders trading at Globus Medical Inc

Over the last 12 years, insiders at Globus Medical Inc have traded over $375,265,297 worth of Globus Medical Inc stock and bought 2,005 units worth $99,824 . The most active insiders traders include David C Paul, Kurt Wheeler és David M Demski. On average, Globus Medical Inc executives and independent directors trade stock every 42 days with the average trade being worth of $11,005,133. The most recent stock trade was executed by Leslie V Norwalk on 11 July 2024, trading 1,000 units of GMED stock currently worth $70,000.

What does Globus Medical Inc do?

globus medical, inc. is a leading musculoskeletal implant manufacturer and is driving significant technological advancements across a complete suite of spinal products. founded in 2003, globus’ single-minded focus on advancing spinal surgery has made it the fastest growing company in the history of orthopedics. globus is driven to utilize superior engineering and technology to achieve pain free, active lives for all patients with spinal disorders. additional information can be accessed at www.globusmedical.com.

Complete history of Mr. Tobin stock trades at Chiasma Inc, Curis Inc, Oxford Immunotec Global PLC, Boston Scientific, Globus Medical Inc, TransMedics és Lyra Therapeutics

Globus Medical Inc executives and stock owners

Globus Medical Inc executives and other stock owners filed with the SEC include:

• David Demski,
  President, Chief Executive Officer, Director
• David Paul,
  Executive Chairman of the Board
• Daniel Scavilla,
  Executive Vice President, Chief Commercial Officer
• David M. Demski,
  CEO, Pres & Director
• Kelly Huller,
  Senior Vice President, General Counsel, Corporate Secretary
• David C. Paul,
  Co-Founder & Exec. Chairman
• Daniel T. Scavilla,
  Exec. VP, Chief Commercial Officer & Pres of Trauma
• Keith Pfeil,
  Chief Financial Officer, Senior Vice President
• Keith W. Pfeil,
  Sr. VP & CFO
• Kelly G. Huller Esq.,
  Sr. VP & Gen. Counsel
• Ann Rhoads,
  Independent Director
• Robert Douglas,
  Independent Director
• James Tobin,
  Independent Director
• Daniel Lemaitre,
  Independent Director
• Steve Zarrilli,
  Independent Director
• David Davidar,
  Independent Director
• Richard Holifield,
  Exec. Officer
• Mike Reeder,
  Exec. Officer
• Steven M. Payne,
  VP & Controller
• A. Brett Murphy,
  Exec. VP of International Sales
• Brian J. Kearns,
  Sr. VP of Bus. Devel. & Investor Relations
• John A De Ford,
  
• Kurt Wheeler,
  Director
• Robert Liptak,
  Director
• Steven Payne,
  Chief Accounting Officer
• Anthony L Williams,
  President
• Stephen T Zarrilli,
  
• Leslie V Norwalk,
  
• Dan Wolterman,
  
• Dan Lemaitre,
  
• A Brett Murphy,
  Executive VP, US Sales
• Eric Schwartz,
  Senior VP and General Counsel
• Sachs & Cogoldman Sachs Gro...,
  
• Lifesciences I, L.P.Clarus ...,
  
• Sachs Pep 2004 Offshore Hol...,
  
• Richard A Baron,
  Senior VP and CFO
• Sachs Group Incgoldman Sach...,
  
• Sachs Private Equity Partne...,